Decision cutpoints for boundary (based on posterior probability)
Source:R/boundsPostprob.R
boundsPostprob.Rd
This function is used to identify the efficacy and futility boundaries based on posterior probabilities, i.e.: Efficacy boundary: find minimum x (xU) where Pr(P>p0|x,n,a,b) >= tU and Futility boundary: find maximum x (xL) where Pr(P>p1|x,n,a,b) <= tL
Arguments
- nvec
a vector of number of patients
- p0
the efficacy threshold parameter in the postprob function
- p1
the futility threshold parameter in the postprob function (default = p0)
- tL
futility boundary probability threshold
- tU
efficacy boundary probability threshold
- a
the alpha parameter of the beta prior of treatment group
- b
the beta parameter of the beta prior of treatment group
Value
A matrix where for each sample size in nvec
, this function
returns the maximum number of responses that meet the futility
threshold (xL), its corresponding response rate (pL), posterior probability
(postL), upper bound of one sided 95% CI for the response rate based on an
exact binomial test (UciL), and the same boundary parameters for efficacy:
the minimal number of responses that meet the efficacy threshold (xU),
the corresponding response rate (pU), posterior probability (postU) and
the lower bound of one sided 95% CI for the response rate based on exact
binomial test (LciU).
Examples
## 40 pts trial with interim looks after each 10 pts.,
## efficacy decision if more than 90% probability to be above 20% ORR,
## futility decision if less than 10% probability to be above 20% ORR,
## with uniform prior (i.e. beta(1, 1)) on the ORR:
boundsPostprob(
nvec = c(10, 20, 30, 40), p0 = 0.20,
tL = 0.10, tU = 0.90, a = 1, b = 1
)
#> nvec xL pL postL UciL xU pU postU LciU
#> 10 10 0 0.0000 0.0859 0.2589 4 0.40 0.9496 0.1500
#> 20 20 1 0.0500 0.0576 0.2161 7 0.35 0.9569 0.1773
#> 30 30 2 0.0667 0.0374 0.1953 9 0.30 0.9254 0.1663
#> 40 40 4 0.1000 0.0664 0.2144 12 0.30 0.9479 0.1831
## From this we see e.g. that at the third IA at 30 pts, we would stop for futility
## if 5 or less patients responded, and for efficacy if 9 or more pts responded.